Immuno-Oncology Investing & Partnering Forum

Facilitating Partnering, Funding & Investment to Advance Immuno-Oncology Drugs

August 30, 2018

Cambridge Healthtech Institute is pleased to announce the Inaugural Immuno-Oncology Investing & Partnering Forum to run as part of the Immuno-Oncology Summit in Boston on August 30, 2018. This timely and focused event brings together early- and late-stage investors with fundraising CEOs and research entrepreneurs to encourage partnering and investment, and to ultimately accelerate immune-oncology therapies to market. This Forum will provide ample opportunity for both investors and CEOs to interact through pre-scheduled 1-1 meetings, as well as interactive panels presented by pharma business development and the VC/investment community. Both late-stage and emerging tech companies will present on the agenda.

Final Agenda

THURSDAY, August 30

7:45 am Registration and Morning Coffee

8:30 State of the Industry Keynote Presentation

Ilan Zipkin, PhD, Vice President, Business Development, Parker Institute for Cancer Immunotherapy

9:15 NEW: Investing in Immuno-Oncology Panel Discussion

In this panel discussion, private, public and strategic investors will discuss their investment strategies. Potential topics of discussion include: What does it take to get an immuno-oncology company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today’s deal terms and valuations? What are the best exit strategies?

Moderator: Margaux Stack-Babich, Program Manager, Immunotherapy Foundation

Panelists: John Gustofson, Managing Director, AbbVie Ventures

Michael Gladstone, Principal, Atlas Venture

Stephen Curtis, PhD, Principal, MPM Capital

10:15 Networking Coffee Break in the Exhibit Hall

11:00 Partnering and Licensing in Immuno-Oncology

Big pharma, biotech and medtech need to act to capitalize new innovations that provide solutions to the global demands in healthcare. This insider panel will discuss their areas of interest for in-licensing novel therapeutics, devices and diagnostics and what they look for in a partner or investment.

Moderator: Maude Tessier, PhD, Vice President, Business Development, Kyn Therapeutics; Former Executive Director, Business Development, Boston Innovation Hub, Merck

Panelists: Claudina Stevenson, PhD, Director, Search and Evaluation, Oncology, AbbVie

Kaan Certel, PhD, Head, Oncology External Innovation, Global Business Development & Licensing, Sanofi

Michael Woo, MBA, Director, Search & Evaluation, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.

12:00 pm Enjoy Lunch on Your Own

1:30 Novel Therapeutics in Cancer Immunotherapy

In this session, we will hear from companies on the cutting edge. Novel drugs are being developed and commercialized, and new pathways are being discovered and targeted. Innovative technology is yielding benefits in development of diagnostics and treatments. Hear from leading companies on their approaches.

Panelists: Richard Purcell, Executive Vice President, Research and Development, Generex Biotechnology, Inc.

Robert Ang, MD, CBO, Neon Therapeutics

RJ Tesi, MD, CEO & CMO, INmune Bio

2:30 Networking Refreshment Break in the Exhibit Hall

3:15 Emerging Immuno-Oncology Targets

With record numbers of immunotherapies in active development, the importance of targets such as the tumor microenvironment is becoming clear. How do you determine what to target? Once you have a target, how do you deliver therapies effectively? This session will preview next-generation products and companies.

Panelists: Len Pagliaro, PhD, CEO, Siva Therapeutics, Inc.

Paul Rennert, President & CSO, Aleta Biotherapeutics, Inc.

James Grady, President, IngenoVax LLC

4:15 Emerging Company Showcase

The inaugural Emerging Company Showcase offers the stage to young immuno-oncology companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs, and executives in the field.

Participants: Charles Garvin, CEO, Riptide Bioscience, Inc.

Romain Micol, President, CEO, Co-Founder, Combined Therapeutics

Michael Olin, PhD, CSO, OX2 Therapeutics

Irving Wainer, CSO, Mitchell Woods Pharmaceuticals

5:15 Networking Reception in the Exhibit Hall

6:30 Close of Immuno-Oncology Investing & Partnering Forum